|
|
Line 29: |
Line 29: |
| ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Chest CT scan | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Chest CT scan |
| |- | | |- |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Antithrombin deficiency<ref name="pmid19141163">{{cite journal |vauthors=Patnaik MM, Moll S |title=Inherited antithrombin deficiency: a review |journal=Haemophilia |volume=14 |issue=6 |pages=1229–39 |date=November 2008 |pmid=19141163 |doi=10.1111/j.1365-2516.2008.01830.x |url=}}</ref><ref name="Al HadidiWu2017">{{cite journal|last1=Al Hadidi|first1=Samer|last2=Wu|first2=Kristi|last3=Aburahma|first3=Ahmed|last4=Alamarat|first4=Zain|title=Family with clots: antithrombin deficiency|journal=BMJ Case Reports|year=2017|pages=bcr-2017-221556|issn=1757-790X|doi=10.1136/bcr-2017-221556}}</ref> | | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Antithrombin deficiency |
|
| |
|
| | style="background: #F5F5F5; padding: 5px;" | + | | | style="background: #F5F5F5; padding: 5px;" | + |
Line 54: |
Line 54: |
| * Antithrombin is a natural anticoagulant that is lost in the urine | | * Antithrombin is a natural anticoagulant that is lost in the urine |
| |- | | |- |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Factor V Leiden mutation<ref name="pmid20626623">{{cite journal |vauthors=Mannucci PM, Asselta R, Duga S, Guella I, Spreafico M, Lotta L, Merlini PA, Peyvandi F, Kathiresan S, Ardissino D |title=The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease |journal=J. Thromb. Haemost. |volume=8 |issue=10 |pages=2116–21 |date=October 2010 |pmid=20626623 |doi=10.1111/j.1538-7836.2010.03982.x |url=}}</ref><ref name="pmid27797270">{{cite journal |vauthors=Campello E, Spiezia L, Simioni P |title=Diagnosis and management of factor V Leiden |journal=Expert Rev Hematol |volume=9 |issue=12 |pages=1139–1149 |date=December 2016 |pmid=27797270 |doi=10.1080/17474086.2016.1249364 |url=}}</ref><ref name="pmid15003896">{{cite journal |vauthors=Van Rooden CJ, Rosendaal FR, Meinders AE, Van Oostayen JA, Van Der Meer FJ, Huisman MV |title=The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis |journal=Haematologica |volume=89 |issue=2 |pages=201–6 |date=February 2004 |pmid=15003896 |doi= |url=}}</ref><ref name="pmid23615845">{{cite journal| author=Dentali F, Pomero F, Borretta V, Gianni M, Squizzato A, Fenoglio L et al.| title=Location of venous thrombosis in patients with FVL or prothrombin G20210A mutations: systematic review and meta-analysis. | journal=Thromb Haemost | year= 2013 | volume= 110 | issue= 1 | pages= 191-4 | pmid=23615845 | doi=10.1160/TH13-02-0163 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23615845 }}</ref> | | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Factor V Leiden mutation |
| | style="background: #F5F5F5; padding: 5px;" | + | | | style="background: #F5F5F5; padding: 5px;" | + |
| | style="background: #F5F5F5; padding: 5px;" | + | | | style="background: #F5F5F5; padding: 5px;" | + |
Line 72: |
Line 72: |
| * Inactivates factor Va and factor VIIIa | | * Inactivates factor Va and factor VIIIa |
| |- | | |- |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Protein C deficiency<ref>{{Cite journal | | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Protein C deficiency |
| | author = [[Bernard Khor]] & [[Elizabeth M. Van Cott]]
| |
| | title = Laboratory tests for protein C deficiency
| |
| | journal = [[American journal of hematology]]
| |
| | volume = 85
| |
| | issue = 6
| |
| | pages = 440–442
| |
| | year = 2010
| |
| | month = June
| |
| | doi = 10.1002/ajh.21679
| |
| | pmid = 20309856
| |
| }}</ref><ref name="pmid11336597">{{cite journal |vauthors=Pescatore SL |title=Clinical management of protein C deficiency |journal=Expert Opin Pharmacother |volume=2 |issue=3 |pages=431–9 |date=March 2001 |pmid=11336597 |doi=10.1517/14656566.2.3.431 |url=}}</ref><ref name=":0">{{Cite journal
| |
| | author = [[Gustavo A. Rodriguez-Leal]], [[Segundo Moran]], [[Roberto Corona-Cedillo]] & [[Rocio Brom-Valladares]]
| |
| | title = Portal vein thrombosis with protein C-S deficiency in a non-cirrhotic patient
| |
| | journal = [[World journal of hepatology]]
| |
| | volume = 6
| |
| | issue = 7
| |
| | pages = 532–537
| |
| | year = 2014
| |
| | month = July
| |
| | doi = 10.4254/wjh.v6.i7.532
| |
| | pmid = 25068006
| |
| }}</ref>
| |
| | style="background: #F5F5F5; padding: 5px;" | + | | | style="background: #F5F5F5; padding: 5px;" | + |
| | style="background: #F5F5F5; padding: 5px;" | + | | | style="background: #F5F5F5; padding: 5px;" | + |
Line 116: |
Line 94: |
| * Risk of thrombotic skin necrosis following warfarin administration | | * Risk of thrombotic skin necrosis following warfarin administration |
| |- | | |- |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Protein S deficiency<ref name=":0" /><ref>{{Cite journal | | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Protein S deficiency<ref name=":0" /> |
| | author = [[Kristi J. Smock]], [[Elizabeth A. Plumhoff]], [[Piet Meijer]], [[Peihong Hsu]], [[Nicole D. Zantek]], [[Nahla M. Heikal]] & [[Elizabeth M. Van Cott]]
| |
| | title = Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American Specialized Coagulation Laboratories
| |
| | journal = [[Thrombosis and haemostasis]]
| |
| | volume = 116
| |
| | issue = 1
| |
| | pages = 50–57
| |
| | year = 2016
| |
| | month = July
| |
| | doi = 10.1160/TH15-12-0918
| |
| | pmid = 27075008
| |
| }}</ref>
| |
| | style="background: #F5F5F5; padding: 5px;" | + | | | style="background: #F5F5F5; padding: 5px;" | + |
| | style="background: #F5F5F5; padding: 5px;" | + | | | style="background: #F5F5F5; padding: 5px;" | + |
Line 150: |
Line 117: |
| * Suspected in patients with a strong family history of VTE | | * Suspected in patients with a strong family history of VTE |
| |- | | |- |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Prothrombin gene mutation<ref name="pmid17474891">{{cite journal| author=Cooper PC, Rezende SM| title=An overview of methods for detection of factor V Leiden and the prothrombin G20210A mutations. | journal=Int J Lab Hematol | year= 2007 | volume= 29 | issue= 3 | pages= 153-62 | pmid=17474891 | doi=10.1111/j.1751-553X.2007.00892.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17474891 }}</ref><ref name="pmid12421139">{{cite journal| author=McGlennen RC, Key NS| title=Clinical and laboratory management of the prothrombin G20210A mutation. | journal=Arch Pathol Lab Med | year= 2002 | volume= 126 | issue= 11 | pages= 1319-25 | pmid=12421139 | doi=10.1043/0003-9985(2002)126<1319:CALMOT>2.0.CO;2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12421139 }}</ref><ref name="pmid236158452">{{cite journal| author=Dentali F, Pomero F, Borretta V, Gianni M, Squizzato A, Fenoglio L et al.| title=Location of venous thrombosis in patients with FVL or prothrombin G20210A mutations: systematic review and meta-analysis. | journal=Thromb Haemost | year= 2013 | volume= 110 | issue= 1 | pages= 191-4 | pmid=23615845 | doi=10.1160/TH13-02-0163 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23615845 }}</ref> | | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Prothrombin gene mutation |
| | style="background: #F5F5F5; padding: 5px;" | + | | | style="background: #F5F5F5; padding: 5px;" | + |
| | style="background: #F5F5F5; padding: 5px;" | + | | | style="background: #F5F5F5; padding: 5px;" | + |
Line 170: |
Line 137: |
| * Hormonal oral contraceptive pills can increase the risk of VTE | | * Hormonal oral contraceptive pills can increase the risk of VTE |
| |- | | |- |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Disseminated intravascular coagulation (DIC)<ref name="pmid25535423">{{cite journal |vauthors=Venugopal A |title=Disseminated intravascular coagulation |journal=Indian J Anaesth |volume=58 |issue=5 |pages=603–8 |date=September 2014 |pmid=25535423 |pmc=4260307 |doi=10.4103/0019-5049.144666 |url=}}</ref><ref name="pmid27276832">{{cite journal |vauthors=Makruasi N |title=Treatment of Disseminated Intravascular Coagulation |journal=J Med Assoc Thai |volume=98 Suppl 10 |issue= |pages=S45–51 |date=November 2015 |pmid=27276832 |doi= |url=}}</ref><ref name="pmid29178991">{{cite journal| author=Cui S, Fu Z, Feng Y, Xie X, Ma X, Liu T et al.| title=The disseminated intravascular coagulation score is a novel predictor for portal vein thrombosis in cirrhotic patients with hepatitis B. | journal=Thromb Res | year= 2018 | volume= 161 | issue= | pages= 7-11 | pmid=29178991 | doi=10.1016/j.thromres.2017.11.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29178991 }}</ref> | | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Disseminated intravascular coagulation (DIC) |
| | style="background: #F5F5F5; padding: 5px;" | + | | | style="background: #F5F5F5; padding: 5px;" | + |
| | style="background: #F5F5F5; padding: 5px;" | + | | | style="background: #F5F5F5; padding: 5px;" | + |
Line 191: |
Line 158: |
| * Portal vein thrombosis | | * Portal vein thrombosis |
| |- | | |- |
| | style="background: #DCDCDC; padding: 5px; text-align: center;" |Antiphospholipid antibody syndrome<ref name="pmid24319251">{{cite journal |vauthors=Lim W |title=Antiphospholipid syndrome |journal=Hematology Am Soc Hematol Educ Program |volume=2013 |issue= |pages=675–80 |date=2013 |pmid=24319251 |doi=10.1182/asheducation-2013.1.675 |url=}}</ref><ref name="pmid19624461">{{cite journal |vauthors=Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG |title=Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis |journal=J. Thromb. Haemost. |volume=7 |issue=10 |pages=1737–40 |date=October 2009 |pmid=19624461 |doi=10.1111/j.1538-7836.2009.03555.x |url=}}</ref><ref name="pmid243192512">{{cite journal| author=Lim W| title=Antiphospholipid syndrome. | journal=Hematology Am Soc Hematol Educ Program | year= 2013 | volume= 2013 | issue= | pages= 675-80 | pmid=24319251 | doi=10.1182/asheducation-2013.1.675 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24319251 }}</ref><ref name="pmid29791828">{{cite journal| author=Garcia D, Erkan D| title=Diagnosis and Management of the Antiphospholipid Syndrome. | journal=N Engl J Med | year= 2018 | volume= 378 | issue= 21 | pages= 2010-2021 | pmid=29791828 | doi=10.1056/NEJMra1705454 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29791828 }}</ref><ref name="pmid23488294">{{cite journal| author=Kornacki J, Wirstlein P, Skrzypczak J| title=[Assessment of uterine arteries Doppler in the first half of pregnancy in women with thrombophilia]. | journal=Ginekol Pol | year= 2012 | volume= 83 | issue= 12 | pages= 916-21 | pmid=23488294 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23488294 }}</ref> | | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Antiphospholipid antibody syndrome |
| | style="background: #F5F5F5; padding: 5px;" | + | | | style="background: #F5F5F5; padding: 5px;" | + |
| | style="background: #F5F5F5; padding: 5px;" | + | | | style="background: #F5F5F5; padding: 5px;" | + |
Line 221: |
Line 188: |
| {{WS}} | | {{WS}} |
| [[Category: (name of the system)]] | | [[Category: (name of the system)]] |
| | <references /> |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Differentiating [disease name] from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]
On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
Diseases
|
Clinical manifestations
|
Para-clinical findings
|
Gold standard
|
Additional findings
|
Symptoms
|
Physical examination
|
Lab Findings
|
Imaging
|
Symptoms of DVT
|
Symptoms of Pulmonary Embolism
|
Symptoms of Myocardial Infarction
|
Tenderness in extremities
|
Edema in extremities
|
Warmth in extremities
|
PT
|
aPTT
|
Doppler ultrasound
|
Chest CT scan
|
Antithrombin deficiency
|
+
|
+
|
-
|
+
|
+
|
+
|
Normal
|
- Reduces the Increase in PTT after administration of heparin
|
- Should be used for diagnosis and follow up
|
- Occlusion of brachiocephalic vein
- Large thrombus in superior vena cava
|
- Decreased plasma antithrombin (AT III) activity
|
- Nephrotic syndrome
- Decreased inhibition of factor II and Xa
- Antithrombin is a natural anticoagulant that is lost in the urine
|
Factor V Leiden mutation
|
+
|
+
|
+
|
+
|
+
|
+
|
N/A
|
↑
|
- Recommended to do weekly
- Proximal DVT is more commonly observed as compared to distal DVT
|
|
|
- Inactivates factor Va and factor VIIIa
|
Protein C deficiency
|
+
|
+
|
-
|
+
|
+
|
+
|
Normal
|
Normal / ↑
|
- Hypercoagulation
- Recurrent venous thromboembolism
|
|
- Protein C functional assay
- ELISA assay: may produce false positive result in cross reaction with rheumatoid factor
|
- Factor VIII elevation in acute phase
- Functional assay should not be performed if patient is on warfarin
- Purpura fulminans (skin necrosis) could be a form of presentation
- Risk of thrombotic skin necrosis following warfarin administration
|
Protein S deficiency[1]
|
+
|
+
|
-
|
+
|
+
|
+
|
Normal
|
Normal / ↑
|
- Hypercoagulation
- Recurrent venous thromboembolism
|
|
- Protein S free antigen assay
|
- Fetal loss
- When performing the gold standard test, beware of interference from samples positive for Factor V mutation, protein C deficiency and oral anticoagulants (rivaroxaban)
- Risk of thrombotic skin necrosis following warfarin administration
- Suspected in patients with a strong family history of VTE
|
Prothrombin gene mutation
|
+
|
+
|
-
|
+
|
+
|
+
|
↑
|
N/A
|
- Proximal DVT is more commonly observed as compared to distal DVT
|
|
- Detection of mutation using restriction enzyme and PCR
- DNA testing for prothrombin G20210A mutation
|
- Mutation causes increased production of prothrombin
- Increased blood levels of prothrombin lead to venous clots in the circulatory system
- Hormonal oral contraceptive pills can increase the risk of VTE
|
Disseminated intravascular coagulation (DIC)
|
+
|
+
|
+/-
|
+
|
+
|
+
|
↑
|
↑
|
- Portal vein thrombosis is observed in patients with coexistent hepatitis B
|
|
|
- Elevated fibrin degradation products (D-dimers)
- Decreased fibrinogen
- Decreased factor V and VIII
- Shistocytes (helmet cells) on peripheral blood smear
- Portal vein thrombosis
|
Antiphospholipid antibody syndrome
|
+
|
+
|
+/-
|
+
|
+
|
+
|
N/A
|
↑
|
- Increased impedance of flow in uterine arteries at 12-20 weeks of gestation
|
|
- Antiphospholipid antibody
- Anticardiolipin antibody
- Lupus anticoagulant
- Anti-β2GPI antibody
|
- Both, arterial and venous thrombosis can occur
- History of spontaneous abortions
- False positive VDRL
- Stroke and transient ischemic attack (TIA) are most common forms of presentation of arterial thrombosis
|
References
- ↑ Invalid
<ref>
tag; no text was provided for refs named :0
Template:WH
Template:WS